Tax Overhaul Boosted Pharma Deals in Q4:17
The dam broke in the fourth quarter of 2017, and pharmaceutical deal makers began acquiring again. The Republican tax overhaul that lowered the tax rate for corporations’ repatriated cash was approved in December, spurring big drug companies to think about mergers and acquisitions once again. Deal volume in the fourth quarter shot up 100% over the previous quarter, to 34 transactions. Q4:17 basically equaled the same quarter in 2016, when 33 deals were announced. This quarter’s deal volume accounts for 35% of the 96 deals announced in the previous 12 months. Source: HealthCareMandA.com, January 2018 Twenty of the 34 announced transactions disclosed a price, making for a total of $6.9... Read More »Laboratories, MRI & Dialysis Deals Dropped in 2016
Deal volume settled down in 2016, following a very busy 2015 in the Laboratories, MRI & Dialysis sector. The 41 deals recorded represent a 21% decline compared with the 52 announced in 2015. Laboratories have had to adapt as hospitals and health systems have merged or closed in recent years. Some labs have evolved to offer coordinated diagnostics: offering tests that give on-the-spot diagnoses, handling bills and lab data from several sources and providers as an aid to accountable care organizations, and focusing on the patient experience to ensure repeat business. At the same time, deal value surged in 2016, up 166% year-over-year to $11.6 billion. Two multi-billion-dollar deals... Read More »Mallinckrodt Divests to Pursue Specialty Pharma Niche
The latest watchword for the pharmaceutical industry is “specialization,” as in “specialization is a safer bet than diversification.” A lot of big-name pharma companies are divesting their non-core businesses in order to target specific therapeutics and disease areas. The most recent example is Mallinckrodt plc (NYSE:MNK), which has sold off approximately $893 million of its assets in the past six months, in order to focus on its specialty pharmaceutical platforms in autoimmune and rare diseases. In August 2016, Mallinckrodt sold its nuclear imaging business for $690 million to IBA Molecular, a global manufacturer and distributor of... Read More »
Werfen Life Divests to Focus on the Hemostasis Market
The growing prevalence of autoimmune and blood disorders has put a spotlight on the science of hemostasis, the process of stopping bleeding and keeping blood within the damaged blood vessel. The coagulation/hemostasis analyzer market is expected to reach $4.84 billion by 2021, according to a report from MarketsandMarkets. Among the products, clinical laboratory analyzers are expected to account for the largest share of the market. Some big name players are already strengthening their hemostasis portfolios. In December 2015, Mallinckrodt plc (NYSE: MNK) purchased a global portfolio of three hemostasis products from The Medicines Company (NASDAQ: MDCO) for an upfront payment of $175... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
